Alzamend Neuro, Inc. (ALZN)
|Net Income (ttm)||-5.05M|
|Trading Day||June 18|
|Day's Range||8.61 - 10.47|
|52-Week Range||8.61 - 33.55|
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option ...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Closing of Initial Public Offering & Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million
LAS VEGAS--(BUSINESS WIRE)---- $AGH #AP--Ault Global Holdings Announces Alzamend Neuro (Nasdaq: ALZN) Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock at $5.00 per Share
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Pricing of Initial Public Offering of 2,500,000 Shares of its Common Stock at a Price to the Public of $5.00 per Share
Alzamend Neuro, Inc. has filed to go public with an IPO on the NASDAQ.
Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our primary target is Alzheimer’s disease. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans... [Read more...]
|IPO Date |
Jun 15, 2021
|Stock Exchange |
|Ticker Symbol |